Remission of refractory Crohn's disease with anti-IL-12/23 therapy in a patient undergoing hemodialysis: A case report.

Abstract

Crohn's disease is a relapsing chronic inflammatory condition of the intestine with increasing prevalence around the world. Biologic therapies are currently widely used and have proved safe and effective in treating moderate to severe Crohn's disease. However, contemporary bibliography contains little information about the use of these drugs in patients with end-stage renal disease undergoing hemodialysis. Here we present a case of a 47-year-old female patient with treatment-refractory Crohn's disease on hemodialysis. In this patient, treatment with the anti-IL-12/23 receptor antibody ustekinumab was effective in inducing and maintaining remission while being safe in administering throughout hemodialysis.

• Authors: Michail Spathakis, Eirini Filidou, George Kolios, Dimitrios Papazoglou, Stergios Vradelis
• Journal: Hemodialysis international. International Symposium on Home Hemodialysis (Hemodial Int) Vol. 27 Issue 3 Pg. E41-E44 (07 2023) ISSN: 1542-4758 [Electronic] Canada
• PMID: 37313986 (Publication Type: Case Reports)
• Copyright: © 2023 International Society for Hemodialysis.

Chemical References

• Interleukin-12
• Ustekinumab

Topics

• Female
• Humans
• Middle Aged
• Crohn Disease (complications, drug therapy)
• Interleukin-12 (therapeutic use)
• Remission Induction
• Renal Dialysis
• Ustekinumab (therapeutic use)
• Treatment Outcome